GLPwatch

A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment

NCT07194317 · Enrolling by invitation

Last updated 2026-05-28

This study is testing different digital tools to see which one is easiest for people with obesity to use when they start a new medication called GLP-1 receptor agonists.

Status Enrolling by invitation Only people invited by the researchers can join.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design open-label (no blinding) study
Participants 50 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2025-09 · est. completion 2026-04
Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT07194317 ↗

Description as written by the study sponsor.

New medications that work on gut hormones such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are helping many people lose weight and are now recommended for treating obesity by the NHS. While these treatments are effective for weight loss, we don't yet know how they affect what people eat or their overall nutrition. Understanding diet before, during, and after treatment is important. Traditional ways of tracking diet, like paper food diaries, can be difficult to use and are time consuming for clinicians to interpret and record in clinical notes. Digital tools like MyFood24, Nutritics-Libro, and Intake24 may offer a better way to record what people eat, but we need to find out if they can be easily used in everyday healthcare settings. The FIDGET study will test how well these digital diet tools can be used in clinics and linked with electronic health records. The study will use surveys and group discussions to understand how patients and healthcare professionals feel about using these tools.

Treatments tested

Main thing measuredUsability
SponsorKing's College London
Conditions studiedObese Patients
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07194317 ↗